Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Medical Dx, V&F Analyse Ink Mass Spec Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Medical Diagnostics and V&F Analyse- und Messtechnik announced Monday that they have formed an alliance based on mass spectrometry technology.

Unde the terms of the alliance, Oxford, UK-based OMD will offer and support V&F's high-performance mass spec analyzers in the UK and Ireland. In addition, OMD will establish a contract batch sample analysis service at its Oxford labs to provide analytical services to customers using V&F's instruments.

The firms also are considering additional opportunities for joint research in areas such as MRSA and C. difficile analysis, sports performance monitoring, and weight loss management.

OMD is developing the Acetone Breath Analyzer, which is based on its infrared absorption spectroscopy technology, and will be used to screen and diagnose type 1 and type 2 diabetes and monitor weight loss in healthy individuals. The firm already uses V&F's mass spec technology as the gold standard with which to compare clinical results from diabetic patients with OMD's laser-based breath products.

Werner Federer, president of Abasam, Austria-based V&F, said that the diabetes and weight-loss markets "represent significant opportunities for both our companies."

Financial and other terms of the alliance were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.